Recently, major researchers, including David Healy, Jon Juriedini, Mickey Nardo, and their colleagues, have brought a great deal of attention to issues of corruption in psychiatric research through their reanalysis of industry-funded trials for psychiatric drugs. This week, fellow reformer and former chair of Duke University’s psychiatry department, Bernard Carroll offers a proposal for addressing these issues through the independent analysis of clinical trial data.
*
For more see MIA founder Robert Whitaker and psychologist Lisa Cosgrove’s recent book, âPsychiatry Under the Influence,â which thoroughly documented the myriad mechanisms of institutional corruption connecting Big Pharma, academic psychiatry, and the FDA
Years ago, Abram Hoffer suggested creating a government institution that would only test clinical claims. The employees would have no ties to industry and do nothing except this work of evaluation of others’ studies and claims, reporting their results to their government overseers.
Report comment